<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Follitropin delta (recombinant human follicle stimulating hormone) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Follitropin delta (recombinant human follicle stimulating hormone) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Follitropin delta (recombinant human follicle stimulating hormone) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="121167" href="/d/html/121167.html" rel="external">see "Follitropin delta (recombinant human follicle stimulating hormone) (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F53125128"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Rekovelle</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F53111295"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Gonadotropin;</li>
<li>
                        Ovulation Stimulator</li></ul></div>
<div class="block doa drugH1Div" id="F53111312"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose should be individualized. Use the lowest dose consistent with the expectation of good results. Over the course of treatment, doses may vary depending on individual patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce81a17a-47b0-4595-85a9-450c42e690f9">Multifollicular development during assisted reproductive technology</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multifollicular development during assisted reproductive technology (ART):</b>
<b>SubQ:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For the first treatment cycle, individual daily doses are based on serum anti-Mullerian hormone (AMH) levels and body weight (measured without shoes and coat just prior to start of stimulation). Individual daily dose should be maintained throughout the stimulation period. Adequate follicular development is generally achieved by the ninth day of treatment (range: 5 to 20 days).</p>
<p style="text-indent:-2em;margin-left:4em;">First treatment cycle:</p>
<p style="text-indent:-2em;margin-left:6em;">AMH &lt;15 pmol/L (irrespective of body weight): 12 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">AMH ≥15 pmol/L: Dose is dependent upon AMH levels (expressed in pmol/L); daily dose decreases from 0.19 to 0.1 mcg/kg by increasing AMH levels. Refer to manufacturer labeling for detailed dosing information.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose: 12 mcg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> As soon as ≥3 follicles ≥17 mm are observed, hCG should be administered to induce final follicular maturation. If patient has excessive ovarian response (&gt;25 follicles with diameter ≥12 mm) do <b>not </b>induce final follicular maturation with hCG and cycle should be cancelled.</p>
<p style="text-indent:-2em;margin-left:4em;">Subsequent treatment cycles: <b>Note:</b> Dose is based on ovarian response to previous cycle.</p>
<p style="text-indent:-2em;margin-left:6em;">Adequate response: Maintain daily dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Hypo-response: May increase daily dose by 25% based on extent of response.</p>
<p style="text-indent:-2em;margin-left:6em;">Hyper-response: Limited data; consult health care provider.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose: 24 mcg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Missed doses:</i></b>Do not double the next dose; health care provider monitoring treatment should be notified.</p></div>
<div class="block dora drugH1Div" id="F53111313"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block doha drugH1Div" id="F53111314"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block adr drugH1Div" id="F53116005"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (1% to 5%), fatigue (2%), nipple pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Pelvic cramps (2% to 4%), pelvic pain (2%), uterine pain (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Polyp (1%, uterine)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal distress, breast tenderness, constipation, diarrhea, dizziness, drowsiness, emotional lability, mastalgia, ovarian torsion, vaginal hemorrhage, vomiting</p></div>
<div class="block coi drugH1Div" id="F53111301"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to follitropins or any component of the formulation; tumor of the ovary, breast, uterus, hypothalamus, or pituitary gland; pregnancy; breastfeeding; gynecologic bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; primary ovarian failure; malformations of sexual organs incompatible with pregnancy; fibroid tumors of the uterus incompatible with pregnancy</p></div>
<div class="block war drugH1Div" id="F53111302"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Abortion: Risk of spontaneous abortion is increased with the use of gonadotropins; causal effect has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ectopic pregnancy: Risk for ectopic pregnancy may be increased in women with tubal abnormalities; intrauterine pregnancy should be confirmed early with ultrasound.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian enlargement: If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian hyperstimulation syndrome: OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012) that may be life threatening. This syndrome may begin within 24 hours of treatment, but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, supportive care. and prevention of thromboembolic complications (ASRM 2016). Therapy with gonadotropins should be stopped.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian neoplasms: Benign and malignant neoplasms have been reported in women receiving multiple-drug therapy for controlled ovarian stimulation; causal effect has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian torsion: Has been reported following gonadotropin treatment; may be related to OHSS, prior ovarian torsion, prior or current ovarian cyst, polycystic ovaries, pregnancy, or prior abdominal surgery. Early diagnosis and prompt detorsion may limit the extent of ovarian damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported with gonadotropin therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic disorders: Women with a current or past history of thromboembolic disorders or with risk factors (eg, personal or family history, severe obesity, thrombophilia) may be at increased risk for occurrence or worsening of arterial or venous thromboembolic events during or following gonadotropin treatment; increased risks are also observed with pregnancy and OHSS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple births: Multiple births may result from the use of these medications; advise patient of the potential risk of multiple births before starting the treatment.</p></div>
<div class="block prod-avail drugH1Div" id="F53124879"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US.</p></div>
<div class="block geq drugH1Div" id="F53952225"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F53125193"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Cartridge, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rekovelle: 12 mcg/0.36 mL ([DSC]); 36 mcg/1.08 mL ([DSC]); 72 mcg/2.16 mL ([DSC]) [contains phenol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rekovelle: 12 mcg/0.36 mL (0.36 mL); 36 mcg/1.08 mL (1.08 mL); 72 mcg/2.16 mL (2.16 mL) [contains phenol]</p></div>
<div class="block adm drugH1Div" id="F53111315"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Administer subQ preferably in the abdomen. The first injection should be administered under the supervision of a health care provider; self-administration of subsequent injections by the patient is at the discretion of the monitoring prescriber. Prefilled cartridges are to be used in conjunction with Rekovelle injection pen.</p></div>
<div class="block use drugH1Div" id="F53111297"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not approved in the US.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multifollicular development during assisted reproductive technology:</b> To stimulate the development of multiple follicles in women undergoing assisted reproductive technology (ART)</p></div>
<div class="block cyt drugH1Div" id="F53098039"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53098036"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F54124429"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Follitropin delta is used for the induction of ovulation. During the course of therapy, if ovaries become abnormally enlarged, treatment may be adjusted to reduce the risk of ovarian hyperstimulation syndrome (OHSS). In this situation, patients should be advised to abstain from intercourse or to use barrier contraceptive methods for at least 4 days.</p></div>
<div class="block pri drugH1Div" id="F53111298"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Follitropin delta is used for the induction of ovulation; use is contraindicated in females who are already pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after assisted reproductive technology (ART) than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics).</p></div>
<div class="block brc drugH1Div" id="F53111300"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if follitropin delta is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Follitropin delta is contraindicated with breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F53111317"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy: Rule out pregnancy and primary ovarian failure; endocrinologic and gynecologic assessment (including pelvic anatomy); fertility potential of partner; serum anti-Mullerian hormone (AMH) to determine initial dose (<b>Note:</b> Manufacturer recommends use of Elecsys AMH immunoassay to determine levels).</p>
<p style="text-indent:-2em;margin-left:2em;">During therapy: Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining or measuring serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration (ASRM 2008b).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of ovarian hyperstimulation syndrome (OHSS) for at least 2 weeks following hCG administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild/moderate OHSS symptoms may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012).</p></div>
<div class="block pha drugH1Div" id="F53111305"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Follitropin delta is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure (ASRM 2008a; ASRM 2008b).</p></div>
<div class="block phk drugH1Div" id="F53111306"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Peak effect: Follicle development: Within cycle</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 9 L</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: ~64%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: SubQ: 40 hours (single dose); 28 hours (daily administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: SubQ: 20 hours (single dose); 10 hours (once daily administration for 7 days)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53144350"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Recovell</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Rekovelle</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25574681">
<a name="25574681"></a>Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/follitropin-delta-recombinant-human-follicle-stimulating-hormone-united-states-not-available-drug-information/abstract-text/25574681/pubmed" id="25574681" target="_blank">25574681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531097">
<a name="22531097"></a>Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/follitropin-delta-recombinant-human-follicle-stimulating-hormone-united-states-not-available-drug-information/abstract-text/22531097/pubmed" id="22531097" target="_blank">22531097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19007609">
<a name="19007609"></a>Practice Committee of the American Society for Reproductive Medicine. Gonadotropin preparations: past, present, and future perspectives. <i>Fertil Steril</i>. 2008a;90(5 Suppl):S13-S20. doi: 10.1016/j.fertnstert.2008.08.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/follitropin-delta-recombinant-human-follicle-stimulating-hormone-united-states-not-available-drug-information/abstract-text/19007609/pubmed" id="19007609" target="_blank">19007609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27678032">
<a name="27678032"></a>Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/follitropin-delta-recombinant-human-follicle-stimulating-hormone-united-states-not-available-drug-information/abstract-text/27678032/pubmed" id="27678032" target="_blank">27678032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19007651">
<a name="19007651"></a>Practice Committee of the American Society for Reproductive Medicine. Use of exogenous gonadotropins in anovulatory women: a technical bulletin. <i>Fertil Steril</i>. 2008b;90(5 Suppl):S7-S12. doi: 10.1016/j.fertnstert.2008.08.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/follitropin-delta-recombinant-human-follicle-stimulating-hormone-united-states-not-available-drug-information/abstract-text/19007651/pubmed" id="19007651" target="_blank">19007651</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rekovelle (follitropin delta) [product monograph]. Toronto, Ontario, Canada; Ferring Inc; November 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121308 Version 16.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
